Hims & Hers Health (NYSE:HIMS) Stock: Insider Oluyemi Okupe Sells 2,000 Shares

October 3, 2026 by InsiderTrades.com

Key Points

Soleil Boughton sold 3,461 Hims & Hers shares at an average price of $29.17, generating approximately $100,957. The Rule 10b5-1 transaction reduced the insider’s position by 1.14%, while Boughton retained 300,809 shares.
Hims & Hers reported quarterly revenue of $753.21 million, up 38.2% year over year and above analyst expectations, but posted an adjusted loss of $0.37 per share versus the consensus estimate of a $0.05 loss.
The stock has a consensus “Hold” rating and an average price target of $32.43, while investors face added uncertainty from securities-fraud litigation and allegations tied to the FTC’s complaint.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $29.70, for a total value of $59,400.00. Following the completion of the transaction, the chief financial officer owned 234,527 shares in the company, valued at $6,965,451.90. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks

Oluyemi Okupe also recently made the following trade(s):

On Tuesday, September 22nd, Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15.
On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.82, for a total transaction of $354,860.66.
On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.99, for a total transaction of $148,090.62.
On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32.
On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87.

Hims & Hers Health Trading Down 1.2%

NYSE:HIMS opened at $28.96 on Friday. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30. The firm has a 50 day moving average of $29.28 and a 200 day moving average of $28.25. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The stock has a market capitalization of $6.76 billion, a price-to-earnings ratio of -45.97 and a beta of 2.44.

Is the Market Right or Wrong About These 4 High Short Interest Stocks?

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same quarter last year, the business earned $0.17 earnings per share. Hims & Hers Health's revenue was up 38.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Truist Financial upped their target price on Hims & Hers Health from $27.00 to $32.00 and gave the company a "hold" rating in a research report on Monday, August 24th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research note on Tuesday, August 11th. TD Cowen boosted their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a "hold" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. started coverage on shares of Hims & Hers Health in a report on Friday, September 11th. They set a "neutral" rating and a $32.00 price objective on the stock. Finally, Morgan Stanley upped their target price on Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and an average price target of $32.43.

MarketBeat Week in Review – 08/24 - 08/28

View Our Latest Analysis on Hims & Hers Health

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. QRG Capital Management Inc. acquired a new position in Hims & Hers Health during the second quarter valued at $248,000. Envestnet Portfolio Solutions Inc. grew its position in Hims & Hers Health by 46.9% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 32,469 shares of the company's stock worth $1,126,000 after purchasing an additional 10,366 shares during the period. Bienville Capital Management LLC acquired a new stake in Hims & Hers Health during the 2nd quarter worth about $27,242,000. Engineers Gate Manager LP acquired a new stake in Hims & Hers Health during the 2nd quarter worth about $232,000. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $147,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Hims & Hers and Hims Australia announced new management appointments, including chief medical officers for the UK and Australia. The moves could strengthen local clinical oversight and support the company’s international expansion strategy. Hims & Hers Names Chief Medical Officers in the UK and Australia
Neutral Sentiment: Two insiders sold a combined 5,461 shares for approximately $160,357. Soleil Boughton sold 3,461 shares at an average of $29.17, while CFO Oluyemi Okupe sold 2,000 shares at $29.70. Both transactions were executed under pre-arranged Rule 10b5-1 plans, and each insider retained substantial holdings, reducing the significance of the sales as a standalone signal. SEC insider filing
Negative Sentiment: Several law firms publicized a securities-fraud class action against Hims & Hers and certain executives. The lawsuit follows the FTC’s federal complaint, which allegedly concerns deceptive business practices and privacy-related misstatements or omissions. Investors who purchased shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates legal costs, reputational risk, and uncertainty around potential financial liability. Hagens Berman class-action announcement

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.